68 weeks
My cravings have calmed down completely and I just naturally eat less now. Very happy with the quality.
Semaglutide
The GLP-1 peptide studied for weight loss and appetite control.
- Mimics GLP-1, a hormone the body releases after eating
- Adults lost 14.9% of their body weight in 68 weeks
- Also studied for heart and kidney health
How to use Semaglutide
Our own 17-step illustrated guide, from mixing to storage.
My cravings have calmed down completely and I just naturally eat less now. Very happy with the quality.
Description
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has transformed the weight management landscape since its development. Originally created for type 2 diabetes management, semaglutide works by mimicking the naturally occurring GLP-1 hormone – a key signalling molecule that your body produces after eating.
When administered, semaglutide binds to GLP-1 receptors in the brain’s appetite control centres, specifically the hypothalamus. This triggers a cascade of effects: reduced hunger signals, increased feelings of satiety after smaller meals, and slowed gastric emptying that keeps you feeling full for longer periods between meals.
How Does Semaglutide Work for Weight Loss?
Unlike traditional diet supplements that rely on stimulants or thermogenics, semaglutide addresses weight management at the hormonal level. It works through three primary mechanisms:
- Appetite suppression: Directly reduces hunger by acting on brain receptors that control food intake and cravings, making it significantly easier to maintain a caloric deficit without constant willpower battles.
- Delayed gastric emptying: Slows the rate at which food leaves your stomach, extending the feeling of fullness after each meal and naturally reducing portion sizes.
- Blood sugar regulation: Enhances insulin secretion in response to meals while suppressing glucagon release, helping to stabilise blood sugar levels and reduce the energy crashes that drive snacking.
What Does the Research Say?
Semaglutide is one of the most extensively studied peptides for weight management. The landmark STEP clinical trial programme, involving over 4,500 participants, demonstrated an average body weight reduction of 12-15% over 68 weeks when combined with lifestyle modifications. Participants reported significantly reduced food cravings, particularly for high-fat and high-sugar foods.
Beyond weight loss, research has shown cardiovascular benefits including reduced risk of major adverse cardiovascular events, improved blood lipid profiles, and decreased systemic inflammation markers – making semaglutide a compelling option for metabolic health optimisation.
Who Is Semaglutide For?
Semaglutide is most commonly used by individuals seeking a science-backed approach to weight management who have found diet and exercise alone insufficient. It is particularly effective for those with a BMI over 27, individuals with metabolic syndrome markers, or anyone looking to break through weight loss plateaus with a hormonal rather than stimulant-based approach.
N Engl J Med, 2021. PubMed →
Nat Med, 2022. PubMed →
N Engl J Med, 2016. PubMed →
JAMA, 2021. PubMed →
Clinical References
- Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017;60(8):1390-1399. PubMed 28526920
- Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. PubMed 32213703
- Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. PubMed 28266779
- Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. PubMed 33269530
- Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619. PubMed 28941314
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PubMed 33667417
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. PubMed 33625476
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. PubMed 33755728
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
- Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468-478. PubMed 36200477
- Milluzzo A, Oteri V, Manuella L, et al. Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis. Int J Obes (Lond). 2026. doi:10.1038/s41366-026-02189-x. PubMed 42668312
Product specifications
- Dosage
- 0.25mg – 2.4mg weekly (titrated)
- Cycle
- 12–16 weeks
- Form
- 5mg lyophilised powder
- Purity
- ≥98%
- Molecular formula
- C₁₈₇H₂₉₁N₄₅O₅₉*
- Storage
- 2–8°C refrigerated
Dosing guide
Category-Specific Dosing Guides
Semaglutide is administered once weekly by subcutaneous injection (an injection into the fatty tissue beneath the skin). Pick a day that suits your schedule and use the same day each week. Some people prefer evening injections before bed, particularly when starting semaglutide, to help minimize disruption from mild nausea. If you are looking to buy Semaglutide Europe, you'll typically find the same once-weekly administration schedule across clinical studies and prescribing information.
-
1
Reconstitute Your Vial
Add 2ml of bacteriostatic water to the 5mg vial to achieve a concentration of 2.5mg/ml.
Use our peptide calculator to calculate concentration, injection volume, and the number of doses available from your vial based on your chosen protocol.
-
2
Follow the Titration Schedule
- Weeks 1–4: 0.25mg (10 units on a U-100 syringe with 2ml reconstitution)
- Weeks 5–8: 0.5mg (20 units)
- Weeks 9–12: 1.0mg (40 units)
- Weeks 13+: 1.7mg–2.4mg, depending on tolerance and response.
Starting low and increasing gradually can help reduce nausea during the first weeks of use. Most Semaglutide for sale follows the same stepwise titration approach.
-
3
Store Correctly Between Doses
Keep refrigerated at 2–8°C after reconstitution. Do not freeze. Store upright and away from light.
Use within 28 days. Write the reconstitution date on the vial.
Semaglutide is often used alongside changes in diet and activity levels. During periods of weight loss, protein intake is commonly set at 1.6–2.2g per kg of body weight. Many weight-loss guidelines recommend at least 150 minutes of moderate physical activity per week.
Shipping and returns
Free shipping on orders over £220.
Fat loss + mitochondrial + gut repair - sema core. · 4 Weeks
Adults lost 14.9% of their body weight in 68 weeks
In a trial of 1,961 adults, semaglutide cut body weight by 14.9%, against 2.4% on placebo.
68 weeks
Half lost 15% or more of their body weight
In the STEP 1 trial, 50.5% of adults on semaglutide lost 15% or more of their body weight. On placebo it was 4.9%. Both groups also followed a lifestyle programme for 68 weeks.
Wilding et al., New England Journal of Medicine, 202124% less food eaten in a day
People ate 24% less energy across all their meals than on placebo. They also reported less hunger and fewer food cravings.
Blundell et al., Diabetes, Obesity and Metabolism, 201720% lower risk of major heart events
In adults aged 45+ with heart disease and no diabetes, 6.5% had a heart attack, stroke or cardiovascular death on semaglutide. On placebo it was 8.0%.
Lincoff et al., New England Journal of Medicine, 202316.0% weight loss with diet and coaching
Adults took semaglutide with a low-calorie diet for the first 8 weeks and 30 counselling visits. They lost 16.0% of body weight, against 5.7% on placebo.
Wadden et al., JAMA, 2021Sources: Wilding JPH et al., New England Journal of Medicine 2021;384(11):989-1002; Blundell J et al., Diabetes, Obesity and Metabolism 2017;19(9):1242-1251; Lincoff AM et al., New England Journal of Medicine 2023;389(24):2221-2232; Wadden TA et al., JAMA 2021;325(14):1403-1413
Rated 4.6 by verified buyers
My cravings have calmed down completely and I just naturally eat less now. Very happy with the quality.
Third order from Morpho. Reconstitution was smooth, no clumping at all. Shipping to Germany took only 2 days.
Leave a Review
Share your experience. Your email won't be published.
How to use Semaglutide
Ready in 4 steps, BAC water included. A complete visual guide to preparing, reconstituting, injecting, and storing your peptides safely. Follow each step in order.
Pre-filled for this product. Adjust values to match your protocol.
Frequently Asked Questions
Common questions answered
